What are the side effects of Sotorasibu (AMG510) produced in Bangladesh Ziska?

Sotoracib (AMG510) is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. Sotoracib produced by Zisika Pharmaceuticals in Bangladesh has been launched on December 12, 2022. What are the side effects of Sotolasibu produced in Bangladesh Ziska?

The most common adverse reactions of sotorasiib are diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity and cough The most common laboratory abnormalities are lymphopenia, decreased hemoglobin, increased AST, increased ALT, decreased calcium, increased alkaline phosphatase, increased urinary protein, and decreased sodium. 50%of patients treated with the drug experienced serious adverse reactions, including pneumonia, hepatotoxicity and diarrhea. The most common serious (grade 3 or above)adverse reactions are ALTincrease, ASTincrease and diarrhea. Fatal adverse reactions include respiratory failure, pneumonia, cardiac arrest, heart failure, gastric ulcer, and pneumonia. 9%of patients permanently discontinued treatment due to adverse reactions. Adverse reactions leading to permanent discontinuation of treatment include hepatotoxicity, ALTincrease, ASTincrease and drug-induced liver injury.

The average distribution volume of sotorasiib(Vd)at steady state is211liters(Coefficient of variation:135%), In vitro sotoracil clothed plasma protein binding rate89%. The mean terminal elimination half-life of sotorasiib is 5 hours. At 960 mg sotoraceib once daily, the steady-state apparent clearance of soteracibwas 26.2 L/hr (CV: 76%). The main metabolic pathways of sotoraxib are non-enzymatic conjugation with CYP3As and oxidative metabolism. If you want to get more high-quality information, you can contact yaode, yaoWe will do our best to help you learn more about high-quality overseas drugs.

xa0

xa0